SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (1378)10/10/1998 8:12:00 AM
From: Omer Shvili   of 1491
 
Neruoinv,

I agree with everything you said, except the comment about the two cohorts. The 48 mg cohort included only 10 patients and so one death here or there could really have affected the results. I think it's still too early to say that there isn't a difference between the dosages. The third cohort will include about 20 patients, and the data will clear this up.
However, you are right that PARS could start phase III before the data from this cohort is available. They can start phase III and if there is major news from the third cohort, change it a bit after 2-4 months (they don't have to give the same dose to all the patients anyway). BTW, I confirmed this with PARS, so it's not pure speculation.

As for negotiations, PARS is allready talking with several companies, and I guess negotiations with others will begin shortly. I expect they sign an agreement by February.

Omer
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News